Status:
UNKNOWN
Bendamustine Plus Rituximab for Mantle Cell Lymphoma: a Multicenter Retrospective Analysis(BR-MCL)
Lead Sponsor:
Samsung Medical Center
Conditions:
Mantle Cell Lymphoma
Eligibility:
All Genders
19+ years
Brief Summary
This study with retrospective data collection does not entail sample size calculation. The study will involve patients who received bendamustine + rituximab for relapsed/refractory mantle cell lymphom...
Detailed Description
1. Inclusion criteria : Patients newly diagnosed with mantle cell lymphoma by a pathologist (based on the 2016 revision of the WHO classification) 1) mantle cell lymphoma 2) leukemic non-nodal mantle ...
Eligibility Criteria
Inclusion
- 1\. Patients newly diagnosed with mantle cell lymphoma by a pathologist (based on the 2016 revision of the WHO classification)
- mantle cell lymphoma
- leukemic non-nodal mantle cell lymphoma
- in situ mantle cell neoplasia 2. Age ≥ 19 years 3. Patients who received bendamustine + rituximab as initial therapy and patients who received bendamustine + rituximab for the treatment of relapsed/refractory condition are both included.
Exclusion
- 1\. Patients whose clinical and pathological data are not available 2. Patients who were not treated with a combination of bendamustine and rituximab
Key Trial Info
Start Date :
January 30 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2020
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04127916
Start Date
January 30 2020
End Date
December 31 2020
Last Update
March 18 2020
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center, 81 Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Seoul, South Korea, 06351
2
Samsung Medical Center, 81, Irwon-ro, Gangnam-gu, Seoul, Republic of Korea
Seoul, South Korea, 06351